Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer.
- DOI
- 10.1080/21655979.2021.2009969
- Published
- 2022 Jan
- Container
- Bioengineered
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/21655979.2021.2009969,
title = {Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer.},
author = {Zhou X and Jin T and Wang L and Zhao E and Xiao X},
year = {2022},
journal = {Bioengineered},
doi = {10.1080/21655979.2021.2009969},
url = {https://doi.org/10.1080/21655979.2021.2009969}
}RIS
TY - JOUR TI - Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer. AU - Zhou X AU - Jin T AU - Wang L AU - Zhao E AU - Xiao X PY - 2022 JO - Bioengineered DO - 10.1080/21655979.2021.2009969 UR - https://doi.org/10.1080/21655979.2021.2009969 ER -
APA
X, Z., T, J., L, W., E, Z., & X, X. (2022). Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer.. Bioengineered. https://doi.org/10.1080/21655979.2021.2009969
Source records
- pubmed · retrieved 2026-09-25T23:56:22.599Z
- europe-pmc · retrieved 2026-09-25T23:56:22.613Z